Document ID: chunk:federal_register_of_legislation:F2024L01389:schedule:1:p59
Version: federal_register_of_legislation:F2024L01389
Segment Type: schedule
Provision Reference: sch 1 (pt 59/66)
Character Range: 191741–196463

whilst receiving chemotherapy for acute myeloid leukaemia or myelodysplastic syndrome; or
                                                      Patient must be considered at high risk of developing an invasive fungal infection due to having acute graft versus host disease (GVHD) grade II, III or IV, or, extensive chronic GVHD, whilst receiving intensive immunosuppressive therapy after allogeneic haematopoietic stem cell transplant; or
                                                      Patient must be undergoing allogeneic haematopoietic stem cell transplant using either bone marrow from an unrelated donor or umbilical cord blood (related or unrelated), and, be considered to be at high risk of developing an invasive fungal infection during the neutropenic phase prior to engraftment; AND
                                                      Must be treated by a health practitioner who is any of: (i) a medical practitioner, (ii) an authorised PBS prescriber who is not a medical practitioner, but who is: (a) sharing care of the patient with at least one medical practitioner; (b) intending to share care of the patient with a medical practitioner.
C16117  P16117  CN16117  Posaconazole                 Prophylaxis of invasive fungal infections including both yeasts and moulds                                                                                                                                                                                                                                                                                                                                          Compliance with Authority Required procedures
                                                      Patient must be considered at high risk of developing an invasive fungal infection due to anticipated neutropenia (an absolute neutrophil count less than 500 cells per cubic millimetre), for at least 10 days whilst receiving chemotherapy for acute myeloid leukaemia or myelodysplastic syndrome; or
                                                      Patient must be considered at high risk of developing an invasive fungal infection due to having acute graft versus host disease (GVHD) grade II, III or IV, or extensive chronic GVHD, and receiving intensive immunosuppressive therapy after allogeneic haematopoietic stem cell transplant; AND
                                                      Must be treated by a health practitioner who is any of: (i) a medical practitioner, (ii) an authorised PBS prescriber who is not a medical practitioner, but who is: (a) sharing care of the patient with at least one medical practitioner; (b) intending to share care of the patient with a medical practitioner.
                                                      Treatment of neutropenia should continue until recovery of the neutrophil count to at least 500 cells per cubic millimetre.
                                                      Patients who have had a previous invasive fungal infection should have secondary prophylaxis during subsequent episodes of neutropenia.
                                                      No more than 6 months therapy per episode will be PBS-subsidised
C16119  P16119  CN16119  Itraconazole                 Systemic aspergillosis                                                                                                                                                                                                                                                                                                                                                                                              Compliance with Authority Required procedures - Streamlined Authority Code 16119
                                                      Must be treated by a health practitioner who is any of: (i) a medical practitioner, (ii) an authorised PBS prescriber who is not a medical practitioner, but who is: (a) sharing care of the patient with at least one medical practitioner; (b) intending to share care of the patient with a medical practitioner.
C16123  P16123  CN16123  Tirofiban                    High risk of unstable angina                                                                                                                                                                                                                                                                                                                                                                                        Compliance with Authority Required procedures - Streamlined Authority Code 16123
                                                      Patient must